Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Syagen Technology was a leading provider of high-speed mass spectrometry and ion source technology used in both the life sciences and security sectors. The company developed proprietary atmospheric pressure photoionization (APPI) and chemical ionization (APCI) sources that enhanced the sensitivity and speed of chemical analysis. In the life sciences, their technology was utilized for high-throughput screening and drug discovery applications, particularly for analyzing non-polar compounds. Syagen was acquired by Morpho Detection in 2011 to integrate its mass spectrometry capabilities into security screening products for explosives and narcotics detection. The company's legacy continues through its ionization technologies which were licensed and integrated into systems by major analytical instrument manufacturers.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Syagen Technology.